Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$36.83 USD
-1.53 (-3.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.80 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LBPH 36.83 -1.53(-3.99%)
Will LBPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LBPH
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
LBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
Other News for LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Bexicaserin Shows Promise in Epilepsy Treatment, Justifying Buy Rating for Longboard Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Longboard Pharmaceuticals (LBPH) and Viridian Therapeutics (VRDN)
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Longboard Pharmaceuticals (LBPH) and R1 RCM (RCM)
Longboard Pharmaceuticals Advances with Promising Seizure Treatment Study